Keywords :
Anticholesteremic Agents/administration & dosage; Belgium; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe/administration & dosage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia/drug therapy; Rosuvastatin Calcium/administration & dosage; Treatment Outcome; Cardiovascular; Cholesterol; Ezetimibe; Fixed; Rosuvastatin; dose combination
Abstract :
[en] LDL cholesterol targets are increasingly strict in recent international guidelines, especially in patients at very high or high cardiovascular risk. To reach these targets, it is recommended to use a potent statin, with a titration up to the maximal tolerated dose and, if not sufficient, to combine ezetimibe, a medication that blocks the intestinal absorption of cholesterol. This association allows reduce the dose of statin, while keeping an excellent cholesterol-lowering efficacy and favouring a good tolerance profile. This article describes the characteristics of a fixed-dose combination of rosuvastatin, the most potent statin, and ezetimibe, commercialized in Belgium under the trade name Myrosor(R).
Scopus citations®
without self-citations
0